Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Glenmark to market BeiGene’s oncology medicines in India
Glenmark to market BeiGene’s oncology medicines in India
Glenmark Pharmaceuticals subsidiary Glenmark Specialty has entered an exclusive agreement to market and distribute two Beigene oncology medicines in India. Tislelizumab and Zanubrutinib will be commer...
China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
Zai Lab and Innoviva Specialty Therapeutics have announced the approval of China’s National Medical Products Administration (NMPA) for Zai’s new drug application (NDA) submitted fo...
Newly identified biomarkers may warn of cancer 7 years before symptoms set in
Newly identified biomarkers may warn of cancer 7 years before symptoms set in
Researchers have found a link between over 1,000 blood proteins and 19 different forms of cancer.
ADHD drug shortage shows signs of letting up, but some patients still struggle
ADHD drug shortage shows signs of letting up, but some patients still struggle
Many of the ADHD (attention-deficit/hyperactivity disorder) medication shortages that have plagued the U.S. for the last two years have now been resolved, the Food and Drug Administration says...
Regeneron wins temporary restraining order preventing Eylea generic launch
Regeneron wins temporary restraining order preventing Eylea generic launch
Regeneron (NASDAQ:REGN) won a temporary restraining order that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, from launching a generic version of its blockbuster eye drug...
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial. Ionis and Biogen are halting the development of their exp...
US FDA Approves Drug For Treating Small Cell Lung Cancer
US FDA Approves Drug For Treating Small Cell Lung Cancer
The U.S. FDA on Thursday approved tarlatamab, a drug for adults with advanced stages of small cell lung cancer.
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
AbbVie and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage Ab...
FDA Approves Updated Label for Altuviiio to include Full Data on Pediatric Patients With Hemophilia A
FDA Approves Updated Label for Altuviiio to include Full Data on Pediatric Patients With Hemophilia A
Antihemophilic factor (recombinant) Fc-VWF-XTEN fusion protein-ehtl was initally approved in February 2023 for adults and children with hemophilia A for prophylaxis and on-demand treatment to ...
NEOsphere Biotechnologies partners with Kymera Therapeutics for Novel Molecular Glue Target Discovery
NEOsphere Biotechnologies partners with Kymera Therapeutics for Novel Molecular Glue Target Discovery
NEOsphere Biotechnologies GmbH, a German biotechnology company pioneering high-throughput proteomics to systematically build broad and unique portfolios of novel degrader targets at scale, today annou...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda  and AC Immune SA today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), ...
FDA clears Qiagen’s respiratory syndromic testing panel
FDA clears Qiagen’s respiratory syndromic testing panel
The FDA has cleared Qiagen’s respiratory syndromic testing panel, the company announced Monday. QIAstat-Dx Respiratory Panel Plus is designed to detect 21 viral and bacterial pathogens that can cau...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand